A close look at six longevity claims, the evidence behind NAD+ and growth hormone, and why healthspan matters for executive health decisions.
On October 15, 2026, The New Zealand Herald republished Melinda Wenner Moyer’s New York Times article challenging six common longevity claims. Its central distinction was between lifespan and healthspan: how long people live versus how long they remain healthy. The reporting brought expert scrutiny to products promoted for lifespan extension and to assumptions about what healthy aging means.
For executives evaluating longevity interventions, the significance is practical. A finding in mice, a changed blood measurement and a demonstrated human health benefit answer different questions. Treating them as interchangeable creates a weak foundation for decisions about long-term health.
The article is a timely examination of those distinctions rather than an announcement of a successful longevity treatment. Its most useful contribution is a clearer standard for judging claims.
Moyer’s article brings together expert interviews and findings from several studies. It is a reporting synthesis rather than a single experiment with one intervention and one defined outcome.
The six assumptions it challenges are:
These claims span research priorities and population health. They also concern treatment evidence and individual expectations. They should not be treated as one scientific proposition.
Steven Austad, a University of Alabama at Birmingham biology professor, told the article that most aging researchers aim to extend healthspan. Additional lifespan could be a side effect of keeping people healthy for longer. That places preserved health at the center of the discussion rather than treating survival alone as the objective.
The product question receives a direct answer. Aladdin Shadyab, a UC San Diego associate professor, told the article that no drug or supplement has been shown to extend human lifespan. The reporting names peptides, resveratrol, NAD+ and growth hormone among products promoted with such claims. Some lifespan findings behind the wider discussion come from worms and mice.
The Herald article cites a 2026 study reporting that whole-blood NAD+ levels remained stable in old age. That finding challenges a simple replenishment argument built around an assumed age-related decline in that particular measurement.
Separately, a 2026 GeroScience study examined community-dwelling adults aged 65 and older. Its cross-sectional analysis reported lower whole-blood NAD+ among participants with frailty than among those without it.
The studies address different questions. One concerns how a blood measurement varies with age. The other concerns an association between that measurement and frailty. Reading claims built around aging biomarkers requires keeping the measurement separate from the health outcome being promised.
For founders and operators, healthspan is a useful planning objective because it centers continued capability. The relevant goal is remaining healthy enough to meet professional demands while retaining capacity outside work. A promise of additional years is incomplete without an account of the health of those years.
This framing also sharpens questions about sustained energy and focus. Instead of accepting a broad longevity claim, an executive can ask which outcome an intervention is supposed to improve. A claim about lifespan should not quietly become a claim about concentration or recovery without evidence addressing those outcomes.
A demanding schedule does not change the standard of proof. Nor does a technical explanation establish that a product produces a meaningful benefit. Scientific plausibility can justify further investigation without settling a purchasing or clinical decision.
Three questions provide a disciplined way to assess the discussion:
These are evidence questions rather than a personal health protocol. Their value is making a claim specific enough to evaluate.
The same discipline applies to weight management. Moyer’s article reports mixed findings in older adults and raises concern about losing muscle and bone alongside fat. For a healthspan discussion, the issue is therefore broader than a lower number on the scale.
ExecuFuel’s focus on long-term health and capability fits this distinction. The objective is clear guidance that makes uncertainty visible rather than replacing one confident longevity slogan with another.
The New York Times report cites a 2025 study finding that US average life expectancy rose by about six months between 2009 and 2019 while healthy life expectancy declined. It also reports that the United States was the only high-income country where healthy life expectancy decreased between 2010 and 2019.
The periods are different and should remain distinct. Together, the reported findings illustrate why longer life and healthier life need separate attention.
This is the article’s clearest population-level challenge to the assumption that progress in survival automatically means progress in health. For an executive thinking about a longer working life, that distinction changes the question from how many years might be added to what those years might contain.
Healthspan is not simply a more appealing label for lifespan. It asks whether additional time is accompanied by health and preserved capability. That is a more demanding outcome than survival alone.
The expert statements are reported commentary. They should not substitute for a review of the underlying studies or an individualized clinical assessment. The coverage also does not supply the full methods of the study reporting stable whole-blood NAD+ with age.
The NAD+ findings have specific boundaries. Stable whole-blood levels do not establish stable levels in every tissue or show that supplementation is useless for every possible outcome. The association between lower NAD+ and frailty does not establish that low NAD+ causes frailty or that raising it reverses frailty. Likewise, an absence of demonstrated lifespan extension is not proof of no biological effect.
Safety findings also require context. The Herald article cites a clinical-trial review linking human growth hormone use in healthy older adults with increased risks of joint pain, swelling and carpal tunnel syndrome. That warning should not be generalized to every patient or to all medically indicated hormone treatment.
The weight-loss discussion is age-sensitive rather than a blanket argument against weight management. The healthy-life-expectancy findings concern the specified US population and periods rather than forecasting an individual’s future. The article also does not establish an executive-specific program for energy, focus or physical function.
The practical response is to treat products marketed for lifespan extension as unproven for that purpose. Personal decisions about supplements, hormones or weight management belong with a qualified clinician who can assess the intended goal and relevant risks. Prevention and preserved function remain appropriate subjects for that conversation without turning this reporting into a universal regimen.
The next meaningful advance would be human research connecting proposed longevity interventions with clearly defined health outcomes. Preserved function and longer healthy life would be more decision-relevant than a biomarker change presented without an established clinical benefit.
For NAD+, the important questions include how blood measurements relate to health outcomes and whether changing those measurements improves those outcomes. For products marketed around lifespan extension, stronger evidence would need to address benefits and adverse effects in the populations being targeted.
A credible industry shift would make those distinctions easier to see. Product claims would identify the outcome studied and the people studied. Biological findings would be presented as biological findings rather than translated automatically into promises of extra years.
For now, the reporting supports a measured outlook: healthspan is a serious research objective that deserves equally serious standards of evidence. The developments worth watching are those that move from plausible mechanisms toward demonstrated human benefit.
Stay connected for research and practical guidance on executive performance, energy, focus, sleep, recovery and longevity. Ideas built for people who want to stay sharp, capable and effective for the long run.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
